Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Koichi Fukunaga

Showing results (1-10 of 342) with videos related to

Pageof 35
Sort By:
Arerugi = [Allergy]|December 10, 2025
[SIGNIFICANCE OF DIGITAL BIOMARKERS IN ASTHMA AND ALLERGY MANAGEMENT]Koichi Fukunaga
Arerugi = [Allergy]|May 24, 2023
[ASTHMA PREVENTION AND MANAGEMENT GUIDELINES 2021]Koichi Fukunaga
Arerugi = [Allergy]|February 21, 2018
[EOSINOPHILS AND ANTI-INFLAMMATORY LIPID MEDIATORS]Koichi Fukunaga
Arerugi = [Allergy]|June 24, 2014
[The mechanism of airway hyperresponsiveness by lipid mediators]Koichi Fukunaga
Frontiers in Immunology|July 12, 2023
Editorial: Heterogeneity of ILC2sHiroki Kabata, Koichi Fukunaga
Respirology (Carlton, Vic.)|July 1, 2026
Contemporary Concise Review 2025: AsthmaJun Miyata, Koichi Fukunaga
Arerugi = [Allergy]|December 16, 2021
[PATHOPHYSIOLOGY AND TREATMENT OF ASTHMA IN PATIENTS WITH EOSINOPHILIC RHINOSINUSITIS AND OTITIS MEDIA]Koichi Fukunaga, Jun Miyata
STAR Protocols|January 31, 2024
Protocol for lentiviral vector-based gene transfection in human ILC2sMisato Irie, Hiroki Kabata, Koichi Fukunaga
Arerugi = [Allergy]|February 25, 2024
[THE INNATE IMMUNE NETWORK AND THERAPEUTIC APPROACHES IN ASTHMA]Rie Baba, Hiroki Kabata, Koichi Fukunaga
Frontiers in Immunology|April 30, 2026
Pro-inflammatory and counter-regulatory modulators of interleukin-5-driven eosinophil programs: a framework for precision medicine in eosinophilic diseasesHisashi Sasaki, Jun Miyata, Koichi Fukunaga
Pageof 35

Showing results (1-10 of 342) with videos related to

Sort By:
Pageof 35
Arerugi = [Allergy]|December 10, 2025
[SIGNIFICANCE OF DIGITAL BIOMARKERS IN ASTHMA AND ALLERGY MANAGEMENT]Koichi Fukunaga
Arerugi = [Allergy]|May 24, 2023
[ASTHMA PREVENTION AND MANAGEMENT GUIDELINES 2021]Koichi Fukunaga
Arerugi = [Allergy]|February 21, 2018
[EOSINOPHILS AND ANTI-INFLAMMATORY LIPID MEDIATORS]Koichi Fukunaga
Arerugi = [Allergy]|June 24, 2014
[The mechanism of airway hyperresponsiveness by lipid mediators]Koichi Fukunaga
Frontiers in Immunology|July 12, 2023
Editorial: Heterogeneity of ILC2sHiroki Kabata, Koichi Fukunaga
Respirology (Carlton, Vic.)|July 1, 2026
Contemporary Concise Review 2025: AsthmaJun Miyata, Koichi Fukunaga
Arerugi = [Allergy]|December 16, 2021
[PATHOPHYSIOLOGY AND TREATMENT OF ASTHMA IN PATIENTS WITH EOSINOPHILIC RHINOSINUSITIS AND OTITIS MEDIA]Koichi Fukunaga, Jun Miyata
STAR Protocols|January 31, 2024
Protocol for lentiviral vector-based gene transfection in human ILC2sMisato Irie, Hiroki Kabata, Koichi Fukunaga
Arerugi = [Allergy]|February 25, 2024
[THE INNATE IMMUNE NETWORK AND THERAPEUTIC APPROACHES IN ASTHMA]Rie Baba, Hiroki Kabata, Koichi Fukunaga
Frontiers in Immunology|April 30, 2026
Pro-inflammatory and counter-regulatory modulators of interleukin-5-driven eosinophil programs: a framework for precision medicine in eosinophilic diseasesHisashi Sasaki, Jun Miyata, Koichi Fukunaga
Pageof 35